GEN Exclusives

More »

GEN News Highlights

More »
Jan 20, 2011

Cellectis Nabs TAL Effector IP from Minnesota and Iowa State Universities

  • Cellectis has negotiated an exclusive license to a targeted genome-engineering technology developed by researchers at the University of Minnesota and Iowa State University. The license deal gives Cellectis rights to all uses of the transcription activator-like (TAL) effector IP in all fields. It claims the technology will complement its own meganuclease platform for genome engineering. “Our teams are already leveraging this new technology, and the first research reagents based on it are expected to come onto the market within 12 months,” notes André Choulika, Cellectis CEO.

    Further details about the new technology were not released, but in October 2010 the Minnesota and Iowa State University teams published a paper describing a new class of sequence-specific nucleases created by fusing TAL effectors to the catalytic domain of the FokI endonuclease. Published in the Genetics Society of America journal Genetics, the paper explains that TAL effectors are proteins secreted by Xanthomonas bacteria when they infect various plant species. The scientists' research also confirmed that both native and custom TAL effector-nuclease fusions directed DNA double-strand breaks to specific, targeted sites. Their paper was titled, "Targeting DNA Double-Strand Breaks with TAL Effector Nucleases".

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »